( OTC-BB:SRNE,OTC-PINK:SRNE )

News from sorrento therapeutics, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Mar 16, 2015, 13:56 ET NantWorks und Sorrento kündigen ihre zweite, umfassende, weltweite Kooperation bei der Entdeckung und Entwicklung neuartiger Immunotherapien gegen Krebs an

- NantCell erwirbt die exklusiven Rechte an Antikörpern, wie den CAR-TNK™ Produkten und den Checkpoint-Inhibitoren PD-1 und PD-L1...


Mar 16, 2015, 09:00 ET NantWorks And Sorrento Announce Second Comprehensive Global Collaboration On Discovery And Development Of Novel Anti-Cancer Immunotherapies

 NantWorks, Inc. and Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), announced today that they have entered into a...


Feb 23, 2015, 09:00 ET Sorrento to Present at Cowen and Company's 35th Annual Health Care Conference

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (Sorrento), an oncology company developing new treatments for cancer and associated...


Feb 05, 2015, 09:00 ET Sorrento to Present at the 17th Annual BIO CEO & Investor Conference

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated...


Feb 02, 2015, 09:00 ET Sorrento Announces Retention of Glen Sato to Provide Strategic Support

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, announced...


Jan 28, 2015, 14:41 ET Sorrento kondigt afronding aan van deelname aan het Cynviloq™ TRIBECA™ registratieonderzoek

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), een oncologiebedrijf dat nieuwe behandelingen voor kanker en aanverwante pijn ontwikkelt,...


Jan 28, 2015, 12:00 ET Sorrento annonce la fin du recrutement dans l'étude TRIBECA™ d'enregistrement Cynviloq™

Sorrento Therapeutics, Inc. (NASDAQ : SRNE ; Sorrento), la société d'oncologie qui développent de nouveaux traitements...


Jan 28, 2015, 09:00 ET Sorrento gibt Ende der Rekrutierung für die Cynviloq™ TRIBECA™-Zulassungsstudie bekannt

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), ein Onkologieunternehmen, das neue Behandlungsmethoden für Krebs und damit verbundene...


Jan 28, 2015, 09:00 ET Sorrento Announces Completion of Enrollment in the Cynviloq™ Registrational TRIBECA™ Study

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, announced today...


Jan 12, 2015, 09:00 ET Sorrento Provides Status Update on the Cynviloq™ Registrational TRIBECA™ Study

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, announced...


Jan 06, 2015, 09:00 ET Conkwest, Sorrento And NantWorks Announce Presentation At The 33rd Annual J. P. Morgan Healthcare Conference By Dr. Patrick Soon-Shiong

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and Conkwest, Inc., an...


Jan 05, 2015, 09:00 ET Sorrento To Present At The 2015 Biotech Showcase And 8th Annual OneMedForum In San Francisco

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and...


Dec 24, 2014, 08:00 ET Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board

 Conkwest, Inc., the Natural Killer Cell Company of the West, developing the proprietary Natural Killer (NK) cell-line platform,...


Dec 19, 2014, 06:00 ET Sorrento and Conkwest Announce Exclusive Global Collaboration

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE;  Sorrento), an oncology company developing new treatments for cancer and associated pain, and...


Dec 15, 2014, 09:25 ET Sorrento Announces Strategic Investment By And Collaboration With Nantworks Founder Dr. Patrick Soon-Shiong For The Advancement Of Cancer Immunotherapies

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, announced today...


Dec 08, 2014, 09:15 ET Sorrento Therapeutics Announces Poster Presentations on its Anti-c-Met/PD-L1 Bispecific Antibodies and Anti-c-Met-Antibody Drug Conjugate at the 37th Annual San Antonio Breast Cancer Symposium

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated...


Dec 03, 2014, 09:30 ET Sorrento To Present At The 2014 Oppenheimer Healthcare Conference

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, today announced...


Nov 12, 2014, 11:00 ET Sorrento To Present At The 2014 Stifel Healthcare Conference

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), today announced that Dr. Henry Ji, President and Chief Executive Officer, will present...


Oct 16, 2014, 06:27 ET Los datos del estudio TRIBECA apoyan el potencial de la bioequivalencia entre Cynviloq y paclitaxel

- Los datos farmacocinéticos iniciales del estudio TRIBECA apoyan el potencial de la bioequivalencia entre Cynviloq y paclitaxel...


Oct 15, 2014, 16:17 ET Les données pharmacocinétiques initiales de l'étude TRIBECA confirment le potentiel de bioéquivalence entre Cynviloq et le paclitaxel lié à de l'albumine

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), une société de produits oncologiques développant de nouveaux traitements...